CRISPR Therapy HAE: Phase 3 Data from Intellia at EAACI 2026
Intellia presented the long-awaited results of phase 3 of CRISPR therapy lonvoguran ziclumeran for hereditary angioedema. Reduction of attacks by 87%, 62% of patients without therapy. Learn more.
